Fall Meeting 2013

The Evidence Behind the Research: FGF-23 and Its Impact on CKD

Sep 21, 2013 12:45pm ‐ Sep 21, 2013 2:30pm

Standard: $20.00
Members: $0.00

Description

Contact hours available until 9/22/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Conflict of Interest Disclosure:
Speaker(s) have no disclosures to declare.

Conference Committee Disclosures:
Dawn Koonkongsatian – Employee, Fresenius Medical Care
Kristin Larson – Employee, NxStage Medical
Denise Murcek – Employee, Fresenius Medical Care
Beth St. John - Employee, Fresenius Medical Care
Lucy Todd – Employee, Baxter Healthcare
Kyra Trappett – Employee, DaVita

Commercial Support and Sponsorship:
Supported by an unrestricted educational grant from Sanofi Renal.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

Objectives:

  • Examine the pathophysiology of metabolic bone disease (MBD) and the importance of FGF-23 and klotho on MBD.
  • Discuss important research findings related to FGF-23 and Klotho and their impact on CKD patients.
  • Determine the changes necessary in policies and practices to improve the management of MBD based upon this new data.

Speaker(s):

You must be logged in and own this session in order to post comments.